• Explore /
  • Poster
  • / AMPLIFY-7P, a first-in-human safety and efficacy trial of adjuvant mKRAS-specific lymph node targeted amphiphile ELI-002 7P vaccine in patients with minimal residual disease–positive pancreatic and colorectal cancer.

AMPLIFY-7P, a first-in-human safety and efficacy trial of adjuvant mKRAS-specific lymph node targeted amphiphile ELI-002 7P vaccine in patients with minimal residual disease–positive pancreatic and colorectal cancer.

Abstract Video & Slides Poster

Authors

null

Craig E. Devoe

Northwell Heath, New York, NY

Craig E. Devoe , Shubham Pant , Zev A. Wainberg , Vincent Chung , Thomas J. George , Pashtoon Murtaza Kasi , Haley VanWyk , Amy Tavares , James Perry , Thian Kheoh , Lisa McNeil , Esther Welkowsky , Peter DeMuth , Christopher M. Haqq , Eileen M. O'Reilly

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Vaccines

Clinical Trial Registration Number

NCT05726864

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 2636)

DOI

10.1200/JCO.2024.42.16_suppl.2636

Abstract #

2636

Poster Bd #

115

Abstract Disclosures

Similar Posters

First Author: Zev A. Wainberg

First Author: Shubham Pant

First Author: Gary Piazza

First Author: Benjamin Adam Weinberg